RecruitingPhase 1NCT07405177
A Study of MK-7240 in Healthy Participants (MK-7240-009)
A Randomized, Open-label, Parallel-group Study to Assess the Pharmacokinetic Bioequivalence of Subcutaneously-administered Tulisokibart Delivered by 2 Different Autoinjectors in Healthy Participants
Sponsor
Merck Sharp & Dohme LLC
Enrollment
330 participants
Start Date
Mar 5, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria1
- Has a body-mass index (BMI) between 18 and 32 kg/m\^2
Exclusion Criteria2
- Has a history of more than 1 episode of herpes zoster infection or history of disseminated herpes zoster infection
- Has a history of or current active tuberculosis (TB) infection or history of latent TB that was not fully treated
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALTulisokibart Form 1
Solution for injection.
BIOLOGICALTulisokibart Form 2
Solution for injection.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07405177
Related Trials
Study of New Magnetic Resonance Imaging Methods of the Brain
NCT000045771 location
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
Predicting Future Errors During Skill Performance
NCT067072071 location
Validation of Energy Expenditure Measures Study
NCT071555641 location
Does Listening to Music Alter the Running Mechanics?
NCT035062822 locations